Three months of romosozumab did not improve hip bone strength, but 12 months did, supporting completion of the full regimen in patients with osteoporosis.
|Slideshows|May 17, 2018
Comorbidities in Spondyloarthritis: A Review
Osteoporosis, cardiovascular disease, cancer, infection . . . which of these comorbidities are of greatest concern in patients with SpA?
Advertisement
Reference1. Moltó A, Nikiphorou E. Comorbidities in spondyloarthritis. Front Med. 2018;5:62. doi:10.3389/fmed.2018.00062.
Advertisement
Related to this article
The new 30-mg/5-mL formulation offers an alternative for adults who have difficulty swallowing capsules.
On World Arthritis Day, TOGETHER-PsA data and 3 rheumatology/derm experts frame GLP-1 agonists as a promising — but not yet proven — adjunct therapy.
At Week 52, ixekizumab plus tirzepatide sustained gains in skin clearance, joint response and metabolic measures versus ixekizumab alone.
Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.
Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
Amgen reported dazodalibep met its primary endpoint in the phase 3 OASIZ-301 trial, improving ESSDAI score in moderate-to-severe systemic Sjögren's disease.
Advertisement
Advertisement